Palisade Bio to Participate in the Piper Sandler Virtual Novel Targets in Immunology Symposium
Rhea-AI Summary
Palisade Bio (Nasdaq: PALI) announced a virtual fireside chat at the Piper Sandler Virtual Novel Targets in Immunology Symposium on Thursday, February 12, 2026, from 1:30 PM–1:55 PM ET. CEO JD Finley and President/CMO Dr. Mitchell Jones will present.
The event includes analyst-led discussions, one-on-one investor meetings for registered attendees, a live webcast on the company Events page at palisadebio.com, and a replay archived for a limited time.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, PALI gained 4.88%, reflecting a moderate positive market reaction. Argus tracked a peak move of +4.8% during that session. Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $13M to the company's valuation, bringing the market cap to $274M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
PALI gained 9.33% while close peers showed mixed moves (e.g., GRI at +7.17%, SXTP at +10.05%, KTTA and TTNP negative). Momentum scanner only flagged SXTP moving down, reinforcing that today’s upside appears stock-specific rather than a broad biotech or immunology rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 05 | Conference participation | Positive | -5.1% | Oppenheimer healthcare conference presentation and investor meetings announcement. |
| Jan 29 | Advisory board change | Positive | -3.6% | Appointment of leading global IBD experts to Clinical Advisory Board. |
| Jan 16 | Scientific abstracts | Positive | -5.1% | Two PALI-2108 abstracts accepted for major IBD conference posters. |
| Jan 07 | Strategic investment | Positive | +5.2% | Up to $500,000 equity investment from Crohn’s & Colitis Foundation IBD Ventures. |
| Dec 30 | Patent grant | Positive | -4.8% | Japanese composition-of-matter patent granted for lead candidate PALI-2108. |
Recent positive corporate and clinical updates have often been followed by short-term share price declines, with only the Crohn’s & Colitis Foundation equity investment seeing a positive next-day reaction.
Over the past few months, Palisade Bio has reported multiple milestones around its lead PDE4 prodrug program PALI-2108, including a Japanese composition-of-matter patent extending into 2041, selection of two abstracts for major IBD conferences, and a strategic equity investment of up to $500,000 from the Crohn’s & Colitis Foundation. The company also engaged investors via conferences and advisory board additions. Despite generally constructive news, four of the last five events saw negative 24-hour price reactions, so today’s conference-related strength contrasts with that pattern.
Regulatory & Risk Context
The company has an effective Form S-3 shelf registration dated August 15, 2025, listing 988,872 shares and estimated offering-related expenses totaling $49,000. The shelf has seen at least one usage via a 424B4 filing on October 2, 2025, indicating pre-established capacity for registered securities offerings.
Market Pulse Summary
This announcement highlights Palisade Bio’s continued investor outreach through a virtual fireside chat at an immunology-focused Piper Sandler symposium. It follows recent progress for PALI-2108, including a Japanese patent running into 2041 and a strategic equity investment of up to $500,000 from the Crohn’s & Colitis Foundation. Investors may watch for future clinical milestones, financing actions under the S-3 registration, and how ongoing conference visibility supports interest in the company’s PDE4 prodrug platform.
Key Terms
pde4 inhibitor medical
prodrugs medical
terminal ileum medical
immunology medical
AI-generated analysis. Not financial advice.
Virtual fireside chat scheduled for Thursday, February 12, 2026, from 1:30 PM to 1:55 PM ET
Access the webcast here
Carlsbad, CA, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced that JD Finley, Chief Executive Officer, and Dr. Mitchell Jones, President and Chief Medical Officer, will participate in a virtual fireside chat at the Piper Sandler Virtual Novel Targets in Immunology Symposium on Thursday, February 12, 2026, from 1:30 PM to 1:55 PM ET.
The symposium will host analyst-led fireside chats and discussions with public and private companies exploring emerging targets and therapeutic approaches in immunology. In addition to the fireside chat, management will be available to participate in one-on-one in-person meetings with qualified members of the investor community who are registered to attend the conference.
A live webcast of the presentation will be accessible on the Events page in the Investors section of the Company’s website at palisadebio.com. A replay will be available following the live event and will be archived for a limited time.
About PALI-2108
PALI-2108 is a once-daily, oral prodrug designed for targeted delivery of PDE4 inhibition to the terminal ileum and colon through local bacterial bioactivation. The prodrug is pharmacologically inactive until it reaches the lower intestine, where bacterial enzymes convert it into the active PDE4 inhibitor at sites of inflammation and fibrosis. This targeted activation strategy prevents absorption in the upper gut, enables sustained local exposure with controlled systemic distribution, and is engineered to reduce peak plasma levels, thereby improving the overall therapeutic index and reducing tolerability limitations such as diarrhea, nausea and headache that have constrained systemic PDE4 inhibitors.
About Palisade Bio
Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”) is a clinical-stage biopharmaceutical company advancing a next generation oral PDE4 inhibitor prodrugs designed to improve pharmacology, tolerability and convenience for patients with inflammatory and fibrotic diseases. Through its differentiated prodrug platform and precision pharmacology strategy, Palisade Bio is committed to transforming proven PDE4 biology into better, safer oral therapies for patients living with chronic inflammatory and fibrotic diseases.
The Company’s lead program, PALI-2108, is a once-daily oral PDE4 inhibitor prodrug designed to be selectively bioactivated in the ileum and colon, initiating targeted PDE4 inhibition at sites of disease while enabling systemic distribution of the active drug. In a recently reported Phase 1b trial, PALI-2108 achieved a
Palisade Bio is now advancing towards a Phase 2 clinical study in UC designed to evaluate clinical remission, response and pharmacodynamic biomarkers over 12 weeks, with an extension phase assessing maintenance of remission. In addition, the Company is completing early studies in FSCD to further characterize PALI-2108’s safety, pharmacology and potential therapeutic benefit across inflammatory bowel disease indications. For more information, please go to www.palisadebio.com.
Forward Looking Statements
Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include but are not limited to: statements regarding the timing and results of clinical trials, the potential mechanisms of action and therapeutic benefits of PALI-2108, and plans for regulatory submissions. These forward-looking statements are based on the Company’s current expectations. Forward-looking statements involve risks and uncertainties. Important factors that could cause actual results to differ materially from those reflected in the Company’s forward-looking statements include, among others, the timing of enrollment, commencement and completion of the Company’s clinical trials; the Company’s reliance on PALI-2108, and its early stage of clinical development; the risk that prior results, such as signals of safety, activity, dosing or durability of effect, observed from preclinical or clinical trials, will not be replicated or will not continue in ongoing or future studies or clinical trials involving the Company’s product candidates in clinical trials focused on the same or different indications; and other factors that are described in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Securities and Exchange Commission (“SEC”) on March 24, 2025, and the Quarterly Reports on Form 10-Q or other SEC filings that are filed thereafter. Investors are cautioned not to put undue reliance on these forward-looking statements. These forward-looking statements speak only as of the date hereof, and the Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908-824-0775
PALI@jtcir.com
FAQ
When will Palisade Bio (PALI) present at the Piper Sandler Virtual Novel Targets in Immunology Symposium?
How can investors watch the Palisade Bio (PALI) fireside chat webcast on February 12, 2026?
Will Palisade Bio (PALI) management be available for investor meetings at the symposium?
Who from Palisade Bio (PALI) will speak at the Piper Sandler immunology symposium?
How long will the Palisade Bio (PALI) webcast replay be available after the symposium?
